Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 8/20 | 0.41 |
| ▸ | MLYCD | O95822 | 2/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 4/20 | 0.32 |
| ▸ | CA9 | Q16790 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2989905 | 0.91 | ALOX5 (0.39) | ALOX5MLYCDTUBBHTR6CA12 | |
| SCHEMBL2989755 | 0.88 | MLYCD (0.51) | ALOX5MLYCDTUBBGCKCA12 | |
| SCHEMBL5960370 | 0.86 | ALOX5 (0.39) | ALOX5MLYCDTUBB | |
| SCHEMBL5005164 | 0.85 | MIF (0.42) | MLYCDGCK | |
| SCHEMBL2975435 | 0.84 | ALOX5 (0.51) | ALOX5MLYCDCA12CA9LMNA | |
| SCHEMBL2986061 | 0.84 | ALOX5 (0.41) | ALOX5MLYCDTUBBCA12CA9 | |
| SCHEMBL2980039 | 0.81 | MLYCD (0.56) | ALOX5MLYCDTUBBCA12CA9 | |
| SCHEMBL2989918 | 0.78 | ALOX5 (0.57) | ALOX5MLYCDTUBBCA12CA9 | |
| SCHEMBL5960294 | 0.74 | ALOX5 (0.46) | ALOX5MLYCDTUBBCA12CA9 | |
| SCHEMBL2985984 | 0.74 | ALOX5 (0.39) | ALOX5MLYCDTUBBCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137371-A1 | Novel Pharmaceutical Compounds | MERCK FROSST CANADA LTD. (CA) | 2010-06-03 | — | — | US | disclosed |
| US-7439260-B2 | 7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | MERCK FORSST CANADA & CO. (CA) | 2008-10-21 | — | — | US | disclosed |
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | GAREAU YVES | 2006-06-01 | — | — | US | disclosed |
| EP-1636222-A1 | 7-[(1,3-THIAZOL-2-YL)THIO]-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108720-A1 | 7- (1, 3-THIAZOL-2-YL)THIO!-COUMARIN DERIVATIVES AND THEIR USE AS LEUKOTRIENE BIOSYNTHESIS INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116406-A1 | 7-(1,3-thiazol-2-yl)thio!-coumarin derivatives and their use as leukotriene biosynthesis inhibitors | LTC4S, LTA4H, CYSLTR1 | ALOX5 17/4885MLYCD 2142/4885TUBB 1628/4885 |
| US-20100137371-A1 | Novel Pharmaceutical Compounds | LTC4S, LTA4H, LTB4R2 | ALOX5 17/4885MLYCD 2597/4885TUBB 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.